# A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain

> **NCT04641273** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 154 (actual)

## Conditions studied

- Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** BAY1817080
- **DRUG:** Placebo for BAY1817080
- **DRUG:** Placebo for Pregabalin
- **DRUG:** Pregabalin

## Key facts

- **NCT ID:** NCT04641273
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-22
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-10-18
- **Target enrollment:** 154 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2022-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641273, "A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04641273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*